GlassScriptPhysician profile
Leonorilda Hines
NPI 1588765374
$3,542.83
in general payments reported to CMS, 2019-2025
37 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $10.83 · 2024: $609 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.89 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $390.73 | 2024-2025 | Jakafi, Monjuvi, Monjuvi |
| Janssen Biotech, INC. | $319.54 | 2024-2025 | Carvykti, Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $294.94 | 2025 | Opdivo, Breyanzi, Opdualag |
| Daiichi Sankyo INC. | $272.57 | 2025 | Datroway, Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $260.88 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $220.12 | 2024-2025 | Reblozyl, Breyanzi |
| Sobi, INC | $188.19 | 2024-2025 | |
| Abbvie INC. | $124.99 | 2025 | |
| Recordati_rare_diseases_inc. | $124.64 | 2025 | Sylvant |
| Jazz Pharmaceuticals INC. | $121.87 | 2025 | |
| Adc Therapeutics America, INC. | $121.86 | 2025 | |
| Glaxosmithkline, LLC. | $121.86 | 2025 | Ojjaara |
| Pfizer INC. | $95.75 | 2025 | |
| Taiho Oncology, INC. | $80.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $77.43 | 2024 | Imfinzi, Calquence |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonorilda Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.